All In MedTech

Device Trial Radar · NCT05241665

First in Human Study

A First in Human Study of the SpectraWAVE Imaging System

Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jul 28, 2022

Primary completion

Apr 21, 2023

Study completion May 21, 2023

Sponsor

Lead sponsor
SpectraWAVE, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 16, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigational, prospective, multi-site, first in human, feasibility evaluation

Conditions

  • Coronary Artery Disease

Interventions

  • SpectraWAVE Imaging SystemDevice

    Coronary imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility EvaluationTime frame: From informed consent to hospital discharge after the SpectraWAVE Imaging System procedure, an average of less than one day.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Angiografia De Occidente S.A

    Cali, Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.